These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia. Neuwirtova R; Fuchs O; Holicka M; Vostry M; Kostecka A; Hajkova H; Jonasova A; Cermak J; Cmejla R; Pospisilova D; Belickova M; Siskova M; Hochova I; Vondrakova J; Sponerova D; Kadlckova E; Novakova L; Brezinova J; Michalova K Ann Hematol; 2013 Jan; 92(1):11-8. PubMed ID: 22965552 [TBL] [Abstract][Full Text] [Related]
5. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts. Malcovati L; Cazzola M Br J Haematol; 2016 Sep; 174(6):847-58. PubMed ID: 27391606 [TBL] [Abstract][Full Text] [Related]
6. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide. Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904 [TBL] [Abstract][Full Text] [Related]
7. Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients. Wu L; Li X; Xu F; Zhang Z; Chang C; He Q Eur J Haematol; 2013 Jun; 90(6):486-93. PubMed ID: 23506134 [TBL] [Abstract][Full Text] [Related]
8. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide. Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710 [TBL] [Abstract][Full Text] [Related]
9. Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche. Buesche G; Teoman H; Schneider RK; Ribezzo F; Ebert BL; Giagounidis A; Göhring G; Schlegelberger B; Bock O; Ganser A; Aul C; Germing U; Kreipe H Br J Haematol; 2022 Jul; 198(1):114-130. PubMed ID: 35362549 [TBL] [Abstract][Full Text] [Related]
10. H2AX deficiency is associated with erythroid dysplasia and compromised haematopoietic stem cell function. Zhao B; Tan TL; Mei Y; Yang J; Yu Y; Verma A; Liang Y; Gao J; Ji P Sci Rep; 2016 Jan; 6():19589. PubMed ID: 26791933 [TBL] [Abstract][Full Text] [Related]
11. [Dyserythropoiesis in myelodysplastic syndrome]. Iwama A Rinsho Ketsueki; 2018; 59(10):2036-2041. PubMed ID: 30305506 [TBL] [Abstract][Full Text] [Related]
12. Deletion 5q MDS: molecular and therapeutic implications. Komrokji RS; Padron E; Ebert BL; List AF Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813 [TBL] [Abstract][Full Text] [Related]
13. Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis. Hopfer O; Nolte F; Mossner M; Komor M; Kmetsch A; Benslasfer O; Reissmann M; Nowak D; Hoelzer D; Thiel E; Hofmann WK Eur J Haematol; 2012 Feb; 88(2):144-53. PubMed ID: 21967505 [TBL] [Abstract][Full Text] [Related]
14. Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS. Mei Y; Zhao B; Basiorka AA; Yang J; Cao L; Zhang J; List A; Ji P Leukemia; 2018 Apr; 32(4):1023-1033. PubMed ID: 29263441 [TBL] [Abstract][Full Text] [Related]
15. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Tehranchi R; Invernizzi R; Grandien A; Zhivotovsky B; Fadeel B; Forsblom AM; Travaglino E; Samuelsson J; Hast R; Nilsson L; Cazzola M; Wibom R; Hellström-Lindberg E Blood; 2005 Jul; 106(1):247-53. PubMed ID: 15755901 [TBL] [Abstract][Full Text] [Related]
16. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Dutt S; Narla A; Lin K; Mullally A; Abayasekara N; Megerdichian C; Wilson FH; Currie T; Khanna-Gupta A; Berliner N; Kutok JL; Ebert BL Blood; 2011 Mar; 117(9):2567-76. PubMed ID: 21068437 [TBL] [Abstract][Full Text] [Related]
17. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q. Lee JH; List A; Sallman DA Eur J Haematol; 2019 Mar; 102(3):203-209. PubMed ID: 30578738 [TBL] [Abstract][Full Text] [Related]
18. Mice with a Mutation in the Mdm2 Gene That Interferes with MDM2/Ribosomal Protein Binding Develop a Defect in Erythropoiesis. Kamio T; Gu BW; Olson TS; Zhang Y; Mason PJ; Bessler M PLoS One; 2016; 11(4):e0152263. PubMed ID: 27042854 [TBL] [Abstract][Full Text] [Related]
19. EDAG mediates Hsp70 nuclear localization in erythroblasts and rescues dyserythropoiesis in myelodysplastic syndrome. Dong XM; Zhao K; Zheng WW; Xu CW; Zhang MJ; Yin RH; Gao R; Tang LJ; Liu JF; Chen H; Zhan YQ; Yu M; Ge CH; Gao HY; Li X; Luo T; Ning HM; Yang XM; Li CY FASEB J; 2020 Jun; 34(6):8416-8427. PubMed ID: 32350948 [TBL] [Abstract][Full Text] [Related]
20. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Caceres G; McGraw K; Yip BH; Pellagatti A; Johnson J; Zhang L; Liu K; Zhang LM; Fulp WJ; Lee JH; Al Ali NH; Basiorka A; Smith LJ; Daugherty FJ; Littleton N; Wells RA; Sokol L; Wei S; Komrokji RS; Boultwood J; List AF Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16127-32. PubMed ID: 24043769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]